Graft Versus Host Disease

Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant Patients

Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant Patients

By

Researchers recently identified CXCL10, a protein that could act as a biomarker for chronic graft-versus-host disease (cGVHD), a long-term adverse effect that develops in some patients after undergoing blood and bone marrow transplant.

Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical Transplantation

Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical Transplantation

By

Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

By

A short-chain fatty acid made by bacteria in the gut could play an important role in GVHD after allogeneic bone marrow transplant in mice. In human patients who receive bone marrow transplants, GVHD can cause severe gut damage.

Antibody Therapy Beneficial for Patients With Leukemia Undergoing Stem Cell Transplant

Antibody Therapy Beneficial for Patients With Leukemia Undergoing Stem Cell Transplant

Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.

Genetic variant increases risk of graft-versus-host disease in HSCT

Genetic variant increases risk of graft-versus-host disease in HSCT

Rejection seen with high-expression allele recipient, low-expression allele donor in HLA-DPB1 mismatches

New test helps guide treatment for bone marrow transplant patients with GVHD

By

A new test can assist in the treatment of patients with graft-versus-host disease (GVHD), an often life-threatening complication of bone marrow and stem cell transplants.

Test predicts response to treatment for graft-versus-host disease (GVHD)

By

A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.

Short chemotherapy regimen can control immune disease after some bone marrow transplants

By

A short course of cyclophosphamide can not only prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate need for the typical 6-month round of immune suppression medicines.

Early detection helps manage chronic graft-vs-host disease complication

By

A simple questionnaire that rates breathing difficulties on a scale of 0 to 3 predicts survival in chronic graft-vs-host disease, according to a new study.

Bortezomib regimen improves stem cell transplantation outcomes

By

Adding bortezomib to standard preventive therapy for GVHD results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to research presented at the 2013 ASH Annual Meeting, in New Orleans.

New drug halves risk of graft-versus-host disease

By

A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a new study from researchers.

How a common chemo drug thwarts graft rejection in bone marrow transplants

By

The chemotherapy drug cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants through an immune system cell that evades the toxic effects of cyclophosphamide.

TRAIL stops graft-vs-host disease after stem cell transplant for leukemia

T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.

Reprogrammed donor cells thwart leukemia relapse

Specially treated T cells infused into high-risk and relapsed leukemia patients can prolong survival after stem cell transplantation.

Experimental combination is equivalent to standard care for prevention of GVHD

By

An experimental drug combination for preventing graft-versus-host disease was not significantly better than the standard regimen on key end points.

Anticancer agent reduces complications after stem-cell transplant

Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.

Higher rates of chronic GVHD seen with peripheral blood stem cell transplants from unrelated donors

By

Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).

GVHD in pediatric HSCT patients: Clinical trials for Rituximab

GVHD in pediatric HSCT patients: Clinical trials for Rituximab

The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.

HIV drug can prevent complications after stem-cell transplant

An HIV drug helped lower the risk of graft-versus-host disease in persons with blood cancer who had stem-cell transplants to rebuild bone marrow.

Older blood cancer patients may benefit from cell transplant regimen

A regimen using minimal-intensity radiation therapy before bone marrow or stem cell transplantation may work for older patients who cannot tolerate stronger pretransplant treatment.

Innovative Strategy Improves Immune Recovery of Mismatched Transplants

By

Scientists have improved a method for bone marrow transplantation from mismatched donors that would help restore the immune system quicker, according to findings presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs